VC-backed Genocea Biosciences prices IPO – Fortune

According to Fortune, Genocea Biosciences has priced its IPO of 5.5 million shares at between $12 and $14 a share. The stock will trade on the NASDAQ under the ticker symbol “GNCA.” Citigroup and Cowen & Co. are the lead underwriters. Based in Cambridge, Mass., Genocea Biosciences is a developer of T-cell vaccines. Genocea’s backers include Polaris Venture Partners, Lux Ventures, Skyline Ventures, Auriga Ventures, The Bill & Melinda Gates Foundation and Morningside Ventures.

Related Posts

Leave a Reply

PEHUB Community

Join the 12493 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

Look Who’s Tweeting

Reuters VC and PE feed

RSS Feed Widget

Groups